Macclesfield, United Kingdom

Michael Karl Bechtold

USPTO Granted Patents = 4 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michael Karl Bechtold: Innovator in Pharmaceutical Formulations

Introduction

Michael Karl Bechtold is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 4 patents to his name, Bechtold's work focuses on enhancing the bioavailability of pharmaceutical compounds.

Latest Patents

One of Bechtold's latest patents involves an immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one. This invention relates to a pharmaceutical formulation that comprises the drug in a solid dispersion with a matrix polymer exhibiting low hygroscopicity and high softening temperature, such as copovidone. The formulation aims to provide a daily pharmaceutical dose of the drug while increasing its bioavailability through the use of the specified matrix polymer.

Career Highlights

Bechtold is currently associated with Kudos Pharmaceuticals Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in developing formulations that improve drug delivery and efficacy.

Collaborations

Throughout his career, Bechtold has collaborated with several professionals in the field, including Julie Kay Cahill and Katja Maren Fastnacht. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Michael Karl Bechtold is a prominent figure in pharmaceutical innovation, with a focus on improving drug formulations. His contributions have the potential to significantly impact the effectiveness of pharmaceutical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…